Trials / Recruiting
RecruitingNCT06667141
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
ACR-2316-101: Phase 1 Study of ACR-2316 in Subjects With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Acrivon Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
Detailed description
The Phase 1 monotherapy clinical trial for ACR-2316 is designed to assess the safety and tolerability of ACR-2316. Additional objectives include the determination of the maximal tolerated dose and recommended Phase 2 monotherapy dose, characterization of the pharmacokinetic profile and pharmacogenomics, and preliminary evaluation of anti-tumor activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACR-2316 | ACR-2316 is an experimental drug |
Timeline
- Start date
- 2024-10-08
- Primary completion
- 2026-08-12
- Completion
- 2026-12-12
- First posted
- 2024-10-31
- Last updated
- 2026-03-23
Locations
15 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06667141. Inclusion in this directory is not an endorsement.